Sustained Seropositivity of Varicella in Healthy Populations in Guangzhou, China
How to cite: He, Q.; Zhu, P.; Xu, Y.; Li, Y.; Luo, L. Sustained Seropositivity of Varicella in Healthy Populations in Guangzhou, China. Preprints 2024, 2024110296. https://doi.org/10.20944/preprints202411.0296.v1 He, Q.; Zhu, P.; Xu, Y.; Li, Y.; Luo, L. Sustained Seropositivity of Varicella in Healthy Populations in Guangzhou, China. Preprints 2024, 2024110296. https://doi.org/10.20944/preprints202411.0296.v1
Abstract
A seroepidemiological study conducted from 2020 to 2022 in Guangzhou, China, aimed to evaluate varicella antibody levels. We measured varicella antibody concentrations using an enzyme-linked immunosorbent assay (ELISA) in a cohort of 3,300 subjects. The mean varicella IgG-specific antibody level was 171.2 mIU/mL (95% CI: 158.9, 184.4), with an overall positivity rate of 67.00% (95% CI: 65.37, 68.60). Varicella antibody levels were found to be influenced by age, vaccination dosage, and history of varicella infection. Notably, antibody concentrations increased with age and the number of vaccinations. Subjects with a vaccination history maintained positive antibody levels six years post-vaccination. We recommend two doses of the varicella vaccine for both children and adults. Before incorporating the varicella vaccine into Guangzhou's routine immunization programs, a comprehensive assessment of disease burden and the economic viability of vaccination strategies is essential.
Keywords
varicella; seroepidemiology; vaccination
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
